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The dimeric anthracene derivative torrubiellin B (1) was isolated from the endophytic fungus 
Acremonium sp. that had been obtained from leaves of the Mangrove plant Sonneratia 
caseolaris. The absolute configuration of 1 was established as (5'R,10'S,10a'R) for the first 
time on the basis of its electronic circular dichroism (ECD) spectra aided with TDDFT-ECD 
calculations. Torrubiellin B (1) exhibited strong anti-tumor activity when tested in vitro 
against several solid cancer cell lines including cells that are resistant against the widely used 
cytostatic drug cisplatin. The IC50 values of 1 against cisplatin sensitive and cisplatin resistant 
cells were in the range of 0.2 - 2.6 µM depending on cell line investigated. 
  
 




Endophytic fungi are known as a rich source of structurally diverse bioactive compounds that 
are often unprecedented in other organisms.1-7 Endophytes which inhabit plants that are 
subject to severe stress conditions are especially interesting for bioprospecting since the fungi 
are assumed to contribute to the survival of their hosts e.g. through accumulation of defense 
metabolites.8-10 We and others have repeatedly shown that Mangrove associated endophytes 
are valuable sources of new bioactive metabolites such as the anti-tumor metabolite 
phomoxanthone A isolated from the Mangrove endophyte Phomopsis longicolla which was 
found to strongly inhibit tumor cells.11 Mangroves are prone to numerous stress factors such 
as changing levels of salinity, periodical flooding and a high incidence of herbivores and of 
pathogenic microbes. Apparently these factors have shaped not only the secondary 
metabolites of the hosts but also that of their associated endophytes.12,13 
In the course of ongoing studies on natural products from Mangrove derived 
endophytes we investigated the endophytic fungus Acremonium sp. that was isolated from 
leaves of the Mangrove plant Sonneratia caseolaris from the island of Hainan (P. R. China). 
Our interest in this fungus had been aroused by the strong anti-tumor activity of its crude 
EtOAc extract when tested in vitro against solid cancer cell lines including cells that are 
highly resistant against the widely used cytostatic drug cisplatin (severe growth inhibition of 
A2780sens cells observed at 10 µg/mL, and of A2780CisR cells at 100 µg/mL). Resistance of 
cancer cells that emerges frequently during chemotherapy is a serious problem for therapy of 
tumor patients and is responsible for the ultimate failure of this therapeutic approach in spite 
of reduction of tumor load during early phases of treatment.14,15 Therefore, new therapeutics 
  
that are able to break resistance against currently employed cytostatic drugs are urgently 
needed. 
During bioassay guided fractionation of the extract of Acremonium sp. torrubiellin B 
(1)16, an asymmetric anthracene derivative was isolated as the active ingredient that is 
responsible for the anti-tumor activity of the fungal extract. Torrubiellin B had first been 
reported from Torrubiella sp. BCC 28517 and the relative configuration of the compound had 
been determined through NOE experiments.17 However, the absolute configuration of the 
compound was unknown so far. The determination of the absolute configuration of 
torrubiellin B (1) especially in light of its prominent activity against cancer cells is an 
important issue during structure determination. Here we report for the first time the absolute 
configuration of torrubiellin B (1) together with its pronounced anti-tumor activity against 
cisplatin sensitive and cisplatin resistant solid cancer cell lines. 
 
Results and discussion 
 
The ethyl acetate extract of the endophytic fungus Acremonium sp. grown on solid rice 
medium was submitted to a bioassay guided chromatographic separation using different 
stationary phases including silica gel, Sephadex LH-20 and semipreparative HPLC on a C18 
reversed phase column. Torrubiellin B (1) was isolated as the major constituent of the extract 
(Figure 1). Compound 1 exhibited a UV/Vis spectrum with three absorption maxima at 206, 
283, and 397 nm that is typical for a conjugated system. In the HRESIMS the 
pseudomolecular ion was detected at m/z 541.1138 [M+H]+ and the molecular formula was 
determined as C30H20O10. Comparison of the MS and NMR data of 1 with those previously 
reported for torrubiellin B suggested that they are identical.17 The structure of 1 was finally 
confirmed as torrubiellin B by careful analysis of COSY, HMBC and ROESY correlations. 
Interpretation of the COSY and HMBC correlations shown in Figure 2 revealed two 
  
anthracene moieties being fused via a cyclopentene ring. The HMBC correlations from H-5’ 
to C-4, C-3, C-10a’ and to C-11 established the connectivity of both monomers. The 
formation of this rare linkage between C-4 and C-5’ and between C-3 and C-10a’ through C-
11 is a structural feature that is inherent to torrubiellins. The linkage of the two anthracene 
units was further corroborated through correlations from H2-11 to H-2 and from H-11 to H-4’ 
in the ROESY spectrum of 1. The relative configuration of C-5’ and C-10’ was deduced from 
ROESY experiments (Figure 4). H-10’ showed ROE correlations to H-5’ and H-11eq and 
furthermore H-11eq had a correlation to H-2, thus indicating the (5’S*,10’R*,10a’S*) relative 
configuration of 1 as shown in Figure 4, which is in agreement with that previously 
reported.17   
Torrubiellin B may be viewed as a 4,5’-linked heterodimeric biaryl of 7-hydroxyemodin and 
dihydro-1,8,10-trihydroxyanthracene-9(4H)-one, in which the rotation along the biaryl axis is 
blocked by the methylene linker between C-3 and C-10a. In contrast to axially chiral biaryls 
of anthracene-9,10-dione monomers,18 torrubiellin B has only central chirality elements due to 
the C-5’, C-10’ and C-10a’ chirality centers and the projection angle between the planes of 
the two monomers is governed by the central chirality. The solution ECD spectra of 
torrubiellin B showed intense negative Cotton effect (CE) at 435 nm and a positive one at 395 
nm accompanied by shoulders and quite a number of other overlapping high-energy ECD 
transitions (Figure 3). For the configurational assignment, solution conformational analysis 
and TDDFT-ECD calculations were performed. The initial MMFF conformational analysis of 
the arbitrarily selected (5’S,10’R,10a’S)-1 resulted in 13 conformers, which were reoptimized 
at B3LYP/6-31G(d) level in vacuo. The reoptimization afforded 2 conformers (96.8% and 
2.9% populations) above 1% Boltzmann-population, which differed only in the orientation of 
hydrogens of the 10’-OH and 3’-Me groups (Figure 4). The ωC-3,C-4,C-5’,C-6’ dihedral angle, a 
parameter describing the relative orientation of the electric transition moments of the two 
subunits, was found +103.17°. TDDFT-ECD calculations of the two low-energy conformers 
  
were carried out at 3 different levels of theory and the Boltzmann-averaged spectra were 
found mirror-image of the experimental ECD curve. The PBE0/TZVP method showed the 
best agreement, the result of which is shown in Figure 4. This allowed determining the 
absolute configuration of torrubiellin B (1) as (+)-(5’R,10’S,10a’R). 
The putative biogenetic formation of 1 and of the structurally related 6,7-dideshydroxy 
derivative torrubiellin A (2) has been suggested to occur through oxidative coupling of 
emodin (5), aloe-emodin (6) or of chrysophanol (7) on the basis of the co-occurrence of these 
monomers in the respective investigated fungal extracts.17 After thorough UV and LCMS 
analysis of the crude ethyl acetate extract of Acremonium sp. analyzed in this study typical 
UV absorption maxima at 223, 250, 273, 293 and 442 nm, as well as a prominent 
pseudomolecular ion peak at 269.5 [M-H]- were detected that account for emodin, but no 
signals were found for aloe-emodin or for chrysophanol. These findings suggest that 1 may 
biogenetically arise from two emodin (5) moieties through subsequent reduction and 
hydroxylation. 
 Compound 1 showed pronounced cytotoxic activity against several human solid 
cancer cell lines including Cal27 (head-neck cancer), Kyse510 (esophageal squamous cell 
carcinoma), HCC38 (breast cancer), A2780 (ovarian cancer) and MDA-MB-231 (breast 
cancer) (Table 1). The cell lines included pairs of cells that are either sensitive (sens) or 
resistant (CisR) towards the well known cytostatic drug cisplatin as indicated by the 
significantly different IC50 values for cisplatin. Torrubiellin B (1) proved to be strongly active 
against all cell lines investigated with IC50 values ranging from 0.3 - 1.5 µM against the 
cisplatin sensitive cells and from 0.2 - 2.6 µM against the cisplatin resistant cells, dependent 
on the cell line investigated. For all cell lines investigated the activity of torrubiellin B (1) was 








The optical rotation was determined with a PerkinElmer 241MC Polarimeter. The 1H, 13C 
and 2D NMR spectra were recorded in DMSO-d6 on a Bruker Avance III 600 NMR 
spectrometer. Mass spectra were measured with a HP110 Agilent Finnigan LCQ Deca XP 
Thermoquest and high- resolution mass spectrometry (HRESIMS) spectra were recorded 
using a UHR-TOF maxis 4G mass spectrometer. ECD spectra were recorded on a J-810 
spectropolarimeter. HPLC analysis was performed with a HPLC system Dionex p580 coupled 
to a UVD340S photodiode array detector; routine detection was at 235, 254, 280, and 340 nm. 
The separation column was prefilled with Eurosphere-10 C18 using a linear gradient of 0.1% 
aqueous HCOOH and MeOH with a flow rate of 1mL/min. Final purification was performed 
via semi-preparative HPLC using a linea gradient of 0.1% aqueous TFA and MeOH over a 
Eurosphere-100 C18 RP column (5µm; 300x8mm) with a flow rate of 5mL/min using a 
Merck Hitachi HPLC system (I-7400 UV detector; L-7100 pump). Column chromatography 
included Silica gel 60M (Macherey.Nagel) and Sephadex LH20 (Sigma). Precoated TLC 
plates (Silica gel 60 F254) were used to monitor fractions; detection was under UV at 254 and 





Mixed torsional/low mode conformational searches were carried out by means of the 
Macromodel 9.9.22319 software using Merck Molecular Force Field (MMFF) with implicit 
solvent model for chloroform applying a 42 kJ/mol energy window. Geometry 
  
reoptimizations of the resultant conformers [B3LYP/6-31G(d) level in vacuo] and TDDFT 
calculations were performed with Gaussian 0920 using various functionals (B3LYP, 
BH&HLYP, PBE0) and TZVP basis set. ECD spectra were generated as the sum of 
Gaussians21 with 2400 cm–1 half-height width (corresponding to ca. 29 nm at 350 nm), using 
dipole-velocity computed rotational strengths. Boltzmann distributions were estimated from 
the ZPVE corrected B3LYP/6-31G(d) energies. The MOLEKEL22 software package was used 




Acremonium sp. was isolated from leaves of the mangrove plant Sonneratia caseolaris, 
collected in October 2005 in Dong Zhai Gang Mangrove Garden, Hainan, P. R. China, and 
cultivated in large-scale following the respective protocol described in the literature.23 The 
fungal strain could be identified after DNA extraction and amplification and after sequencing 
of ots ITS region according to the literature.24 The sequence data was submitted to GenBank, 
accession number FR822815.1.  
 
Extraction and isolation 
 
After 4 weeks of cultivation the fungi were extracted with EtOAc. The dried crude extract 
(1g) was submitted to VLC separation. The last fraction (0.1% methanolic TFA) containing 1 
was further separated over a Sephadex LH-20 column affording F1-F10 fractions. Fractions 6 
and 7 were combined and purified using semipreparative HPLC with an eluting gradient of 





The cytotoxicity was tested against the following human carcinoma cell lines obtained from 
DSMZ: A2780 (ovarian), Cal27 (tongue), Kyse510 (esophagus), HCC38 (triple-negative 
mamma carcinoma), and MDA-MB-231 (triple-negative mamma carcinoma). The CisR cell 
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Table 1. Cytotoxic activities of 1 
 IC50 (µM) in various cell linesa,b 
Compound Cal27 Kyse510 HCC38 A2780 
MDA-MB-
231 
 sens CisR sens CisR sens CisR sens CisR sens CisR 
1 0.3 2.1 1.2 0.2 0.4 0.7 0.3 0.5 1.5 2.6 
Cisplatin 2.9 6.7 1.8 6.8 3.5 27.9 1.5 11.7 13.9 38.1 
 
a Incubation for 72 h. 




Figure 1. Structure of torrubiellin B (1). 
Figure 2. Key COSY (bold lines) and HMBC (arrows) correlations of torrubiellin B (1). 
Figure 3. Experimental spectrum of 1 in MeCN and PBE0/TZVP-calculated ECD spectrum of 
the two low-energy conformers (> 1%) of (5’S,10’R,10a’S)-1 in vacuo. Bars represent the 
calculated rotational strength values of the lowest-energy conformer. 
Figure 4. Key long-range ROE correlations shown on the overlapped lowest-energy computed 
conformers of (5’R,10’S,10a’R)-1. 
  
 
Figure 1. Structure of torrubiellin B (1). 
 
 




Figure 3. Experimental spectrum of 1 in MeCN and PBE0/TZVP-calculated ECD spectrum 
of the two low-energy conformers (> 1%) of (5’S,10’R,10a’S)-1 in vacuo. Bars represent the 
calculated rotational strength values of the lowest-energy conformer. 
  
 
Figure 4. Key long-range ROE correlations shown on the overlapped low-energy computed 
conformers of (5’R,10’S,10a’R)-1.  
  
Highlights 
• A dimeric anthracene derivative was isolated from the endophyte Acremonium sp. 
• The absolute configuration of torrubiellin B was established by ECD calculations. 
• Torrubiellin B showed strong anti-tumor activity against several cancer cell lines. 
